Previous studies have demonstrated that NF-κB and MAPKs inhabitation by pharmacological activators could protect against LPS-induced ALI in mice, suggesting that NF-κB and/or MAPKs are potential therapeutic targets for ALI (Everhart et al., 2006; Zhou et al., 2019). This evidence concerns the gene NFKB1 and acute respiratory distress syndrome.